ZORECIMERAN

CUREVAC MRNA-BASED VACCINE IMMUNOGEN CANDIDATE AGAINST COVID-19 CV-07050101 CV07050101 CVNCOV MESSENGER RNA (MRNA), 5'-CAPPED, ENCODING A FULL-LENGTH CODON-OPTIMISED PRE-FUSION STABILIZED CONFORMATION VARIANT (K986P AND V987P) OF THE SARS-COV-2 (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; NC_045512.2) SPIKE (S) GLYCOPROTEIN, FLANKED BY 5' AND 3' UNTRANSLATED REGIONS; THE 3' UNTRANSLATED REGION COMPRISES A PART OF THE HUMAN ALPHA GLOBIN GENE 3' UTR SEQUENCE ELEMENT, A SYNTHETIC POLY(A) TAIL AND A POLY(C)-RICH SEQUENCE FOLLOWED BY A HISTONE STEM LOOP SEQUENCE AS A 3' TAIL. IMMUNOLOGICAL AGENT FOR ACTIVE IMMUNIZATION (ANTI-SARS-COV-2) RNA (RECOMBINANT 5'-(M7G-(5'->5')-PPP-AM)-CAPPED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 PRE-FUSION SPIKE GLYCOPROTEIN (986-PROLINE,987-PROLINE)-SPECIFYING 3'-TAILED MESSENGER R9515), INNER SALT zorecimeran [INN] Zorecimeran [WHO-DD]